Lite Strategy

Lite Strategy Equity Turnover

Equity Turnover of Lite Strategy (LITS) as of Nov 10, 2026.

Equity Turnover

0.00

Last updated:

Equity Turnover of Lite Strategy is 2025 0.00 . Equity Turnover of Lite Strategy was 2024 1.98 . It decreases by % lower compared to the previous year.

The Lite Strategy Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.03 USD
Jan 1, 2019
0.10 USD
Jan 1, 2020
0.36 USD
Jan 1, 2021
0.70 USD
Jan 1, 2022
0.78 USD
Jan 1, 2023
1.98 USD
Jan 1, 2024
1.98 USD
Jan 1, 2025
0.00 USD
The Lite Strategy Equity Turnover history
YEAREquity TurnoverYoY
0.00-100.00%
1.98-0.25%
1.98+155.32%
0.78+10.38%
0.70+95.37%
0.36+250.54%
0.10+220.19%
0.03-92.99%
0.46—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

On Eulerpool you can find the complete historical development of Equity Turnover Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Lite Strategy with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Lite Strategy

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Lite Strategy